Influx Healthtech Limited, a pharmaceutical products manufacturing company, is poised to enter the capital markets with an Initial Public Offering (IPO) valued at ₹58.57 crores. This offering comprises a fresh issue of 50 lakh equity shares and an offer for sale of 11 lakh equity shares. The subscription window for this IPO opens on Wednesday, June 18, 2025, and concludes on Friday, June 20, 2025. The company is expected to list on the NSE SME platform on Wednesday, June 25, 2025, marking a significant milestone in its growth trajectory.
The equity shares, each bearing a face value of ₹10, are being offered within a price band of ₹91 to ₹96 per share, with a lot size of 1,200 shares. Retail investors may participate with a minimum investment of ₹1,09,200 for one lot, while High Net-worth Individuals (HNIs) may subscribe with a minimum of ₹2,30,400 for two lots. The allotment of shares is scheduled for announcement on Monday, June 23, 2025, followed by the listing on Wednesday, June 25, 2025. As Influx Healthtech Limited prepares to make its public debut, it presents investors with a compelling opportunity within India’s pharmaceutical sector.
Influx Healthtech Limited IPO is a fundraise worth ₹58.57 crores comprising a combination of fresh issue 50 lakh shares and offer for sale of 11 lakh shares reserved for the market maker R.K. Stock Holding Private Limited. Qualified Institutional Buyers are being offered not more than 50% of the net issue, retail investors are being offered not less than 35% of the net issue and Non-Institutional Investors (NIIs) / High Net-worth Individuals (HNIs) are being offered not less than 15% of the net issue. The IPO will be available for subscription from June 18, 2025, to June 20, 2025, providing an opportunity for investors looking to gain a stake in the pharmaceutical space.
| Influx Healthtech IPO date | June 18, 2025 - June 20, 2025 |
| Price band | ₹91 to ₹96 per share |
| Face value | ₹10 per share |
| Lot size | 1,200 shares |
| Issue type | Book Built Issue IPO |
| Fresh issue size | 50,00,400 shares amounting to ₹48.00 crores |
| Offer for sale | 11,00,400 shares amounting to ₹10.56 crores |
| Total issue size | 61,00,800 shares amounting to ₹58.57 crores |
| Listing at | NSE SME |
| Market maker portion | 3,06,000 shares - R.K.Stock Holding Pvt Ltd |
| Shareholding post-issue | 1,81,50,000 shares |
| Shareholding pre-issue | 1,81,50,000 shares |
The Influx Healthtech Limited IPO opens for subscription on June 18, 2025, and closes on June 20, 2025, with allotment scheduled for June 23, 2025.
| IPO open date | June 18, 2025 (Wednesday) |
| IPO close date | June 20, 2025 (Friday) |
| Basis of allotment | June 23, 2025 (Monday) |
| Initiation of refunds | June 24, 2025 (Tuesday) |
| Credit of shares to Demat account | June 24, 2025 (Tuesday) |
| Listing date on NSE SME | June 25, 2025 (Wednesday) |
| Cut-off time for UPI mandate confirmation | 5 PM on June 20, 2025 (Friday) |
Influx Healthcare Private Limited started its journey in September 2020 with a clear focus on healthcare. It works as a trusted contract manufacturer, helping companies across different industries bring their products to life. With three facilities in Thane, Maharashtra, spread across more than 36,000 square feet, Influx handles a wide range of products including tablets, softgels, gummies, skincare and haircare solutions. Whether it's a nutritional supplement, an herbal formulation or a homecare product, the team supports it with care and precision.
What sets Influx apart is its commitment to walking the entire journey with its clients. From developing the product to manufacturing it and ensuring all regulatory requirements are met, the company takes care of it all. This allows clients to focus on what they do best is creating great products. As of June 11, 2025, Influx has a team of 163 dedicated employees. Backed by experienced leadership, a strong focus on quality, and a growing client base, the company continues to grow as a trusted partner in the healthcare and wellness space.
Influx Healthtech intends to utilise the net proceeds from its IPO to support strategic expansion across multiple divisions. A significant portion is allocated towards setting up a dedicated manufacturing facility for its Nutraceutical division, while some amount is earmarked for establishing a facility for the Veterinary Food division. Additionally, a portion of the proceeds will be directed towards the purchase of machinery for the Homecare and Cosmetic division. The remaining funds will be used for general corporate purposes, enabling the company to strengthen its overall operational capabilities.
Influx Healthtech Limited's revenue increased by 5% and profit after tax (PAT) rose by 19% between the financial year ending with March 31, 2025 and March 31, 2024.
As of March 31, 2024, the key performance indicators reflect the company's financial health with a Return on Equity of 36.98%, Return on Capital Employed (ROCE) at 49.17% and a Debt-to-Equity ratio of 0.01. The Return on Net-Worth (RoNW) stands at 36.98%, and the PAT Margin was 12.75%. The Price to Book Value was 7.62. The company’s market capitalisation is ₹222.24 crores.
| Period Ended | March 31, 2025 | March 31, 2024 | March 31, 2023 |
| Revenue | 104.99 | 100.10 | 76.07 |
| Assets | 70.30 | 41.10 | 28.30 |
| Net Worth | 36.15 | 22.87 | 11.65 |
| Profit After Tax | 13.37 | 11.22 | 7.20 |
| Reserves & Surplus | 18.00 | 22.85 | 11.63 |
| Total Borrowing | 0.22 | 0.32 | 0.80 |
Amount in ₹ crores
The pre-IPO EPS is at ₹7.36 while the post-IPO EPS will be ₹5.77. Similarly, the pre-IPO Price to Earnings ratio is 13.04 and will become 16.63 post-IPO.
Influx Healthtech Limited demonstrates notable strength through its extensive and diverse product portfolio, encompassing over 3,500 SKUs across nutraceuticals, cosmetics, ayurvedic formulations, veterinary feed, and homecare products. This breadth not only allows the company to mitigate risks tied to overdependence on a single product line but also enables it to cater to varied consumer needs across high-growth markets. Coupled with its exceptional client retention rate of over 98.5%, supported by well-established relationships with reputed industry players, Influx reflects a foundation of trust, service quality, and consistency.
Further strengthening its position, the company benefits from advanced manufacturing capabilities and rigorous compliance with global standards, including WHO-GMP, FDA, ISO, and HACCP certifications. These standards are upheld across its three leased facilities in Thane, Maharashtra, reinforcing its credibility and readiness for international expansion. With high capacity utilisation, strong R&D innovation including first-to-market formulations and a nearly debt-free balance sheet, Influx showcases financial robustness. Its rising revenue, improved margins, and strategic deployment of IPO funds all point towards a well-managed enterprise, led by an experienced team capable of navigating future growth.
Despite its recent successes, Influx Healthtech is still a young company, having been founded in 2020. Its limited operating history may raise concerns about its long-term resilience, especially in comparison to more established players in the CDMO space. Investors may find it challenging to assess how the company will perform across different economic cycles or regulatory environments given the lack of a prolonged track record.
Additionally, the company’s revenue is heavily skewed towards the nutraceutical segment, which accounts for close to 90% of its earnings. This concentration introduces vulnerability; any slowdown or regulatory shift in this sector could significantly impact financial performance. The geographical focus on a few Indian states and the clustering of its operations in Palghar, Maharashtra, adds further risk, as regional disruptions, be they regulatory, environmental, or logistical could affect the company disproportionately.
Being an early public investor in Influx Healthtech Limited may offer a meaningful opportunity to engage with the company’s growth journey within the pharmaceutical manufacturing sector. However, prospective investors are encouraged to undertake a thorough assessment of various considerations including the company’s operational history, financial stability, industry dynamics, and long-term strategy in alignment with their own investment goals and risk tolerance. It is advisable to consult the offer document in detail and seek independent professional guidance, where appropriate, to make a well-informed investment decision regarding this IPO.
What is the Influx Healthtech Limited IPO?
The Influx Healthtech Limited IPO is an NSE SME offering fresh issue of 50 lakh shares and offer for sale of 11 lakh shares with a face value of ₹10, aiming to raise ₹58.57 crores. The price band has been set between ₹91 to ₹96 per share, with a minimum order quantity of 1200 shares. This IPO will be open for subscription from June 18, 2025, to June 20, 2025. Rarever Financial Advisors Private Limited is the book-running lead manager, Maashitla Securities Private Limited is the registrar while R.K.Stock Holding Private Limited is the market maker.
When will the Influx Healthtech IPO open?
The Influx Healthtech Limited IPO will open for subscription on June 18, 2025, and will close on June 20, 2025.
When is the Influx Healthtech IPO listing date?
The tentative listing date for the Influx Healthtech Limited IPO is Wednesday, June 25, 2025.
For android only